WGS Analysis of COVID-19 Positive Patients

We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronavirus Infection COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Vanda Investigational Site

Cleveland, Ohio, 44106, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ability and acceptance to provide written informed consent and fluent in English.
Men or women between 18-100+ years, inclusive.
Willing to comply with study procedures.
SARS-CoV-2 positive test result as confirmed by a RT-PCR assay with a sputum or nasopharyngeal sample (either done prior to or at the screening visit).

Treatment and study plan

Primary outcomes

Associations with severity and outcomes

Time frame: 3 months

Clinical associations with human and viral genetics

Sponsors and collaborators

Lead sponsor

Vanda Pharmaceuticals

Industry

Registry information

Official study title

Whole Genome Sequencing Analysis of of SARS-CoV-2 Positive Patients

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2022
First posted: Apr 20, 2020
Registry last updated: Mar 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed